GlassScriptPhysician profile
Jillian Glaude Johnson
NPI 1447739230
$4,835.34
in general payments reported to CMS, 2019-2025
35 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $1,082 · 2023: $818 · 2024: $1,306 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.43 | 2021-2025 | |
| Novo Nordisk INC | $467.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $427.89 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $356.03 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $348.70 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $268.93 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $255.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $249.30 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.11 | 2022-2025 | Jardiance, Ofev |
| Pfizer INC. | $164.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.13 | 2021-2025 | Airsupra, Breztri, Lokelma |
| Astellas Pharma US INC | $156.69 | 2023-2024 | Veozah, Myrbetriq |
| Corcept Therapeutics | $145.88 | 2022-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.46 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $97.73 | 2021-2024 | Vaxneuvance, Gardasil 9, Verquvo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $74.15 | 2022-2023 | Livalo, Seglentis |
| Axsome Therapeutics, INC. | $73.44 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.11 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $62.82 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $57.77 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $40.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.52 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $38.89 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $35.83 | 2022 | |
| Shield Therapeutics INC | $32.56 | 2023-2025 | Accrufer |
| Vanda Pharmaceuticals INC. | $25.96 | 2024 | Fanapt |
| Lundbeck LLC | $19.74 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $19.54 | 2021 | |
| Amgen INC. | $15.49 | 2021 | |
| Janssen Biotech, INC. | $15.13 | 2025 | Balversa, Akeega, Erleada |
| Actelion Pharmaceuticals US, INC. | $15.12 | 2024 | Opsumit, Uptravi |
| Idorsia Pharmaceuticals US INC | $14.72 | 2022 | |
| Dexcom, INC. | $14.28 | 2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $13.61 | 2022 | |
| Cmp Pharma, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.